Syncom Formulations (India), a company in the Pharmaceuticals industry, reported revenue of ₹137 crore and net profit of ₹25 crore for the September 2026 quarter.
Syncom Formulations (India) (NSE: SYNCOMF) closed at ₹21.90 on 20 Nov 2026, up 36.9% over the past year. Its market capitalisation is ₹2,059 crore and it trades at 22.0 times earnings.
Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.